Insights on methotrexate in psoriatic disease

Jacqueline E. Greb, Ari M. Goldminz, Alice B. Gottlieb

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


The folic acid analogue methotrexate is used as an anti-neoplastic agent and treatment for inflammatory disorders including psoriasis, dermatomyositis, lupus erythematous, sarcoidosis, and systemic sclerosis. Despite the introduction of newer biologic agents, methotrexate remains a first-line systemic therapy for many patients with disorders of chronic inflammation. Here we briefly describe the current clinical evidence for methotrexate use in psoriatic disease, our current understanding of methotrexate's anti-inflammatory properties, and the future role of methotrexate in the treatment of immune mediated disorders.

Original languageEnglish
Pages (from-to)61-64
Number of pages4
JournalClinical Immunology
StatePublished - 1 Nov 2016
Externally publishedYes


  • Adenosine
  • Cardiovascular disease
  • Methotrexate
  • Psoriasis
  • Psoriatic arthritis
  • T-cell


Dive into the research topics of 'Insights on methotrexate in psoriatic disease'. Together they form a unique fingerprint.

Cite this